|
1
|
Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers.
|
Clin Cancer Res
|
2011
|
2.44
|
|
2
|
Concurrent trastuzumab and HER2/neu-specific vaccination in patients with metastatic breast cancer.
|
J Clin Oncol
|
2009
|
2.04
|
|
3
|
CD4 regulatory T cells in human cancer pathogenesis.
|
Cancer Immunol Immunother
|
2006
|
1.47
|
|
4
|
Antibody immunity to the p53 oncogenic protein is a prognostic indicator in ovarian cancer.
|
J Clin Oncol
|
2006
|
1.31
|
|
5
|
Effect of dose on immune response in patients vaccinated with an her-2/neu intracellular domain protein--based vaccine.
|
J Clin Oncol
|
2004
|
1.19
|
|
6
|
Level of HER-2/neu protein expression in breast cancer may affect the development of endogenous HER-2/neu-specific immunity.
|
Mol Cancer Ther
|
2008
|
1.15
|
|
7
|
Tumor antigen-specific T-cell expansion is greatly facilitated by in vivo priming.
|
Clin Cancer Res
|
2007
|
1.01
|
|
8
|
Recognition of breast cancer cells by CD8+ cytotoxic T-cell clones specific for NY-BR-1.
|
Cancer Res
|
2006
|
0.93
|
|
9
|
HER-2/neu vaccine-primed autologous T-cell infusions for the treatment of advanced stage HER-2/neu expressing cancers.
|
Cancer Immunol Immunother
|
2013
|
0.84
|
|
10
|
Common adjuvant breast cancer therapies do not inhibit cancer vaccine induced T cell immunity.
|
Breast Cancer Res Treat
|
2008
|
0.81
|
|
11
|
Cancer vaccines: the role of tumor burden in tipping the scale toward vaccine efficacy.
|
J Clin Oncol
|
2005
|
0.81
|
|
12
|
Fatal Bacillus cereus sepsis following resolving neutropenic enterocolitis during the treatment of acute leukemia.
|
Am J Hematol
|
2003
|
0.81
|
|
13
|
Peptide-based vaccines in breast cancer.
|
Breast Dis
|
2004
|
0.80
|
|
14
|
HER-2/neu vaccines.
|
Cancer Chemother Biol Response Modif
|
2003
|
0.78
|